JP5072588B2 - ４−ヒドロキシタモキシフェンを用いた良性乳房疾患の治療および予防 - Google Patents

４−ヒドロキシタモキシフェンを用いた良性乳房疾患の治療および予防 Download PDF

Info

Publication number
JP5072588B2
JP5072588B2 JP2007504377A JP2007504377A JP5072588B2 JP 5072588 B2 JP5072588 B2 JP 5072588B2 JP 2007504377 A JP2007504377 A JP 2007504377A JP 2007504377 A JP2007504377 A JP 2007504377A JP 5072588 B2 JP5072588 B2 JP 5072588B2
Authority
JP
Japan
Prior art keywords
hydroxy tamoxifen
tamoxifen
use according
breast disease
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2007504377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007535505A5 (https=
JP2007535505A (ja
Inventor
ネストゥール、 エリザベート ル
Original Assignee
ラボラトワール ブザン アンテルナスィヨナル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04290761A external-priority patent/EP1579856A1/en
Priority claimed from US10/805,528 external-priority patent/US7507769B2/en
Application filed by ラボラトワール ブザン アンテルナスィヨナル filed Critical ラボラトワール ブザン アンテルナスィヨナル
Publication of JP2007535505A publication Critical patent/JP2007535505A/ja
Publication of JP2007535505A5 publication Critical patent/JP2007535505A5/ja
Application granted granted Critical
Publication of JP5072588B2 publication Critical patent/JP5072588B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2007504377A 2004-03-22 2005-03-10 ４−ヒドロキシタモキシフェンを用いた良性乳房疾患の治療および予防 Expired - Lifetime JP5072588B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/805,528 2004-03-22
EP04290761A EP1579856A1 (en) 2004-03-22 2004-03-22 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP04290761.8 2004-03-22
US10/805,528 US7507769B2 (en) 2004-03-22 2004-03-22 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
PCT/EP2005/003286 WO2005092309A1 (en) 2004-03-22 2005-03-10 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen

Publications (3)

Publication Number Publication Date
JP2007535505A JP2007535505A (ja) 2007-12-06
JP2007535505A5 JP2007535505A5 (https=) 2008-04-24
JP5072588B2 true JP5072588B2 (ja) 2012-11-14

Family

ID=34961912

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007504377A Expired - Lifetime JP5072588B2 (ja) 2004-03-22 2005-03-10 ４−ヒドロキシタモキシフェンを用いた良性乳房疾患の治療および予防

Country Status (16)

Country Link
EP (1) EP1748770B1 (https=)
JP (1) JP5072588B2 (https=)
CN (1) CN1946387B (https=)
AT (1) ATE391499T1 (https=)
AU (1) AU2005227072B2 (https=)
CA (1) CA2559748C (https=)
DE (1) DE602005005986T2 (https=)
DK (1) DK1748770T3 (https=)
ES (1) ES2306111T3 (https=)
MX (1) MXPA06010914A (https=)
NO (1) NO336767B1 (https=)
NZ (1) NZ549817A (https=)
PL (1) PL1748770T3 (https=)
PT (1) PT1748770E (https=)
RU (1) RU2357726C2 (https=)
WO (1) WO2005092309A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515041A1 (fr) * 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
ATE80152T1 (de) * 1987-04-21 1992-09-15 Heumann Pharma Gmbh & Co Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en.
DE4407742C1 (de) * 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
DE69825495T2 (de) * 1998-12-23 2005-07-28 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
RU2188000C1 (ru) * 2001-09-27 2002-08-27 Нестерук Владимир Викторович Лекарственное средство на основе тамоксифена
PT1317921E (pt) * 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
WO2004054557A2 (en) * 2002-12-18 2004-07-01 Laboratoires Besins International Treatment of mastalgia with 4-hydroxy tamoxifen
JP4684655B2 (ja) * 2002-12-18 2011-05-18 ラボラトワール ブザン アンテルナスィヨナル ４−ヒドロキシタモキシフェンによる乳房密度低下
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
PL1694319T3 (pl) * 2003-12-15 2009-01-30 Besins Healthcare Lu Sarl Zastosowanie 4-hydroksytamoksyfenu do wytwarzania leku do leczenia ginekomastii

Also Published As

Publication number Publication date
NO20064609L (no) 2006-10-11
NZ549817A (en) 2010-06-25
ATE391499T1 (de) 2008-04-15
WO2005092309A1 (en) 2005-10-06
HK1096595A1 (en) 2007-06-08
CA2559748A1 (en) 2005-10-06
CA2559748C (en) 2013-05-28
CN1946387A (zh) 2007-04-11
EP1748770B1 (en) 2008-04-09
DK1748770T3 (da) 2008-08-04
EP1748770A1 (en) 2007-02-07
PL1748770T3 (pl) 2008-09-30
AU2005227072B2 (en) 2010-08-19
AU2005227072A1 (en) 2005-10-06
JP2007535505A (ja) 2007-12-06
NO336767B1 (no) 2015-10-26
RU2357726C2 (ru) 2009-06-10
MXPA06010914A (es) 2006-12-15
DE602005005986D1 (de) 2008-05-21
RU2006137280A (ru) 2008-04-27
ES2306111T3 (es) 2008-11-01
DE602005005986T2 (de) 2009-06-04
PT1748770E (pt) 2008-07-16
CN1946387B (zh) 2011-08-31

Similar Documents

Publication Publication Date Title
JP4684655B2 (ja) ４−ヒドロキシタモキシフェンによる乳房密度低下
JP5490346B2 (ja) ４−ヒドロキシタモキシフェンによる乳癌の予防および治療
US8048927B2 (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
JP4938237B2 (ja) ４−ヒドロキシタモキシフェンによる乳房痛の治療
JP4682129B2 (ja) ４−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防
JP5489407B2 (ja) ４−ヒドロキシタモキシフェンの化学的に安定な組成物
EP1579856A1 (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
JP5072588B2 (ja) ４−ヒドロキシタモキシフェンを用いた良性乳房疾患の治療および予防
JP5069469B2 (ja) 女性化乳房治療用の薬剤を製造する際の４−ヒドロキシタモキシフェンの使用
HK1079453A (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
MXPA05013435A (en) Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110909

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120613

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120713

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120807

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120821

R150 Certificate of patent or registration of utility model

Ref document number: 5072588

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150831

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term